Apretude HIV PrEP Description
ViiV Healthcare's Apretude HIV PrEP is a long-acting injectable that has recently gained its first regulatory approval for use in HIV prevention in the USA for at-risk adults and adolescents weighing at least 35kg to reduce the risk of sexually acquired HIV-1 infection.
Individuals must have a negative HIV-1 test before receiving it. It is not currently approved for use in HIV prevention anywhere outside of the USA.
ViiV Healthcare is located at 980 Great West Road, Brentford, Middlesex, TW8 9GS, UK.
Apretude (cabotegravir extended-release injectable suspension) has been approved for PrEP to reduce the risk of sexually acquired HIV.
Apretude is given first as two initiation injections administered one month apart and then every two months thereafter. Patients can either start their treatment with Apretude or take oral cabotegravir (Vocabria) for four weeks to assess how well they tolerate the drug.
July 28, 2022 - ViiV Healthcare announced the signing of a new voluntary licensing agreement for patents relating to cabotegravir long-acting for HIV pre-exposure prophylaxis to help enable access in the least developed, low-income, lower-middle-income, and Sub-Saharan African countries.
December 20, 2021 - U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV.